This marks the third BTD granted to olverembatinib in China, with the first BTD granted in March 2021, for the treatment of patients with chronic-phase chronic myeloid leukemia (CML-CP ...

Pharma major, Biocon Pharma, has received final approvals from the U.S. Food and Drug Administration (FDA) for its ...

By Daniella Parra Ascentage Pharma (NASDAQ: AAPG; HKEX) said that its drug Olverembatinib is the first China-approved ...

Dasatinib is prescribed for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in adults.

In The Lancet Hematology, Jorge E Cortes and colleagues1 report a phase 1/2 study on vodobatinib in patients with resistance ...

Zydus Lifesciences Ltd on Wednesday (March 5) said it has received final approval from the United States Food and Drug ...

Dasatinib is the generic version of Sprycel® tablets, a medication widely used for treating Ph+, chronic myeloid leukemia ...

Ascentage Pharma (AAPG) announced that its drug, olverembatinib, has been granted a Breakthrough Therapy Designation by the Center for Drug ...

Meanwhile, a New Drug Application (NDA) for another one of Ascentage Pharma’s key drug candidates, the novel Bcl-2 selective inhibitor lisaftoclax (APG-2575), has already been accepted and granted the ...